Study S001925

A Study Investigating Pharmacokinetic Properties When Dosing Different Formulations of Oral Peptide Therapeutics in Healthy Male Participants

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT05129891
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 384
Start: 2021-11-03
Primary completion: 2023-02-26
Lead sponsor: Novo Nordisk A/S
Conditions: Healthy Volunteers; High Blood Cholesterol Levels; Type 2 Diabetes
Interventions: DRUG:Semaglutide D; DRUG:Semaglutide G; DRUG:Semaglutide H; DRUG:Semaglutide I; DRUG:NNC0385-0434 B; DRUG:NNC0385-0434 C; DRUG:NNC0385-0434 D; DRUG:NNC0385-0434 E
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1266-0672; EUDRACT_NUMBER:2021-001452-34

Registered primary outcomes

AUC0-24h,API,day10; area under the API plasma concentration-time curve from 0 to 24 hours after the 10th dose [From pre-dose PK sample (0 hours) at day 10 to PK sample 24 hours after dose administration]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.